These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36999709)

  • 1. A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.
    Sato Y; Vatsan R; Joshi BH; Husain SR; Puri RK
    Curr Mol Med; 2024; 24(6):758-770. PubMed ID: 36999709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
    Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
    Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
    Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
    Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.
    Nakashima H; Terabe M; Berzofsky JA; Husain SR; Puri RK
    J Immunol; 2011 Nov; 187(10):4935-46. PubMed ID: 22013118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV).
    Zheng Q; Chen D; Li P; Bi Z; Cao R; Zhou B; Chen P
    Virus Genes; 2007 Dec; 35(3):585-95. PubMed ID: 17922181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
    Kioi M; Seetharam S; Puri RK
    Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.
    Mintz A; Gibo DM; Madhankumar AB; Cladel NM; Christensen ND; Debinski W
    Cancer Biother Radiopharm; 2008 Oct; 23(5):581-9. PubMed ID: 18976118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
    Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
    Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-13 receptor-directed cancer vaccines and immunotherapy.
    Nakashima H; Husain SR; Puri RK
    Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL13 Fused
    Uludağ D; Karakaş N
    Anticancer Res; 2021 Jul; 41(7):3471-3480. PubMed ID: 34230142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of human dendritic cells by recombinant modified vaccinia virus Ankara vectors encoding survivin and IL-2 genes in vitro.
    Tao R; Li L; Huang W; Zheng L
    Hum Gene Ther; 2010 Jan; 21(1):98-108. PubMed ID: 19715401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique IL-13Rα2/STAT3 mediated IL-13 regulation detected in lung conventional dendritic cells, 24 h post viral vector vaccination.
    Roy S; Liu HY; Jaeson MI; Deimel LP; Ranasinghe C
    Sci Rep; 2020 Jan; 10(1):1017. PubMed ID: 31974500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
    Hodge JW; Higgins J; Schlom J
    Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.
    Leland P; Degheidy H; Lea A; Bauer SR; Puri RK; Joshi BH
    Clin Transl Med; 2024 May; 14(5):e1664. PubMed ID: 38685487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.
    Nakashima H; Fujisawa T; Husain SR; Puri RK
    J Transl Med; 2010 Nov; 8():116. PubMed ID: 21067607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
    Carroll MW; Overwijk WW; Chamberlain RS; Rosenberg SA; Moss B; Restifo NP
    Vaccine; 1997 Mar; 15(4):387-94. PubMed ID: 9141209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
    Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
    Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
    Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
    Front Immunol; 2021; 12():715000. PubMed ID: 34819930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
    Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
    Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.